Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruolan Wang

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Open Forum Infectious Diseases|January 12, 2024
Very-Low-Level Viremia, Inflammatory Biomarkers, and Associated Baseline Variables: Three-Year Results of the Randomized TANGO StudyRuolan Wang, Mark Underwood, Josep M Llibre, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 12, 2024
Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196Stéphane De Wit, Fabrice Bonnet, Olayemi Osiyemi, et al.
Journal of Medicinal Chemistry|August 20, 2004
Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitorsFrançoise Gellibert, James Woolven, Marie-Hélène Fouchet, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 26, 2022
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized TrialOlayemi Osiyemi, Stéphane De Wit, Faïza Ajana, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 18, 2020
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical TrialsJean van Wyk, Chloe Orkin, Rafael Rubio, et al.
Nature Communications|April 14, 2026
Rational design of a Kappa opioid receptor peptide agonist with attenuated β-arrestin signalingHuanhuan Zhang, Ruolan Wang, Pan Shi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 7, 2020
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO StudyJean van Wyk, Faïza Ajana, Fiona Bisshop, et al.
Bioorganic & Medicinal Chemistry Letters|December 30, 2006
N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3Richard M Angell, Francis L Atkinson, Murray J Brown, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Open Forum Infectious Diseases|January 12, 2024
Very-Low-Level Viremia, Inflammatory Biomarkers, and Associated Baseline Variables: Three-Year Results of the Randomized TANGO StudyRuolan Wang, Mark Underwood, Josep M Llibre, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 12, 2024
Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196Stéphane De Wit, Fabrice Bonnet, Olayemi Osiyemi, et al.
Journal of Medicinal Chemistry|August 20, 2004
Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitorsFrançoise Gellibert, James Woolven, Marie-Hélène Fouchet, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 26, 2022
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized TrialOlayemi Osiyemi, Stéphane De Wit, Faïza Ajana, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 18, 2020
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical TrialsJean van Wyk, Chloe Orkin, Rafael Rubio, et al.
Nature Communications|April 14, 2026
Rational design of a Kappa opioid receptor peptide agonist with attenuated β-arrestin signalingHuanhuan Zhang, Ruolan Wang, Pan Shi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 7, 2020
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO StudyJean van Wyk, Faïza Ajana, Fiona Bisshop, et al.
Bioorganic & Medicinal Chemistry Letters|December 30, 2006
N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3Richard M Angell, Francis L Atkinson, Murray J Brown, et al.
Pageof 7